TCM
ATRA icon

Tang Capital Management’s Atara Biotherapeutics ATRA Stock Holding History

Tang Capital Management’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-75,196
Closed -$447K – 203
2025
Q1 		$447K Hold
75,196
– – 0.02% 186
2024
Q4 		$1M Hold
75,196
– – 0.07% 144
2024
Q3 		$611K Hold
75,196
– – 0.04% 132
2024
Q2 		$639K Sell
75,196
-1
-0% -$15 0.07% 103
2024
Q1 		$1.3M Buy
+75,197
New +$1.34M 0.14% 83

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.57B AUM 26.96% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Tang Capital Management's ATRA Position: Q2 2025 in Review

Tang Capital Management sold out of Atara Biotherapeutics (ATRA) in Q2 2025, closing a stake of 75,196 shares — an estimated $447K sold.

Tang Capital Management first reported a position in ATRA in Q1 2024 and held it in 5 quarters. The position peaked at $1.3M in Q1 2024. 32 funds tracked by Wall St. Rank hold ATRA as of Q2 2025.

  • Tang Capital Management reported no remaining Atara Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • Tang Capital Management sold 75,196 Atara Biotherapeutics shares in Q2 2025, an estimated $447K.
  • Tang Capital Management first reported a position in Atara Biotherapeutics in Q1 2024 and held it in 5 quarters.
  • Tang Capital Management's Atara Biotherapeutics position peaked at $1.3M in Q1 2024.
  • 32 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2025.

Based on Tang Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.